ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical stage biopharmaceutical company, has entered into a warrant inducement agreement with a single institutional investor. The agreement includes the immediate exercise of existing Series A-2 and A-3 Warrants at a reduced exercise price of $0.67, generating gross proceeds of $2.0 million.
In exchange for exercising the existing warrants, the investor will receive new Series A-4 unregistered warrants to purchase up to 6,124,930 shares of common stock in a private placement. The new warrants will have an exercise price of $0.67 and will expire five years from stockholder approval. The transaction is expected to close around July 9, 2025.
ZyVersa Therapeutics (Nasdaq: ZVSA), una societ脿 biofarmaceutica in fase clinica, ha stipulato un accordo di incentivo sui warrant con un singolo investitore istituzionale. L'accordo prevede l'esercizio immediato dei warrant esistenti Serie A-2 e A-3 a un prezzo di esercizio ridotto di 0,67 $, generando proventi lordi per 2,0 milioni di dollari.
In cambio dell'esercizio dei warrant esistenti, l'investitore ricever脿 nuovi warrant Serie A-4 non registrati per acquistare fino a 6.124.930 azioni ordinarie in un collocamento privato. I nuovi warrant avranno un prezzo di esercizio di 0,67 $ e scadranno cinque anni dopo l'approvazione degli azionisti. La transazione 猫 prevista per concludersi intorno al 9 luglio 2025.
ZyVersa Therapeutics (Nasdaq: ZVSA), una empresa biofarmac茅utica en etapa cl铆nica, ha firmado un acuerdo de incentivo de warrants con un 煤nico inversor institucional. El acuerdo incluye el ejercicio inmediato de los warrants existentes de las Series A-2 y A-3 a un precio de ejercicio reducido de 0,67 $, generando ingresos brutos de 2,0 millones de d贸lares.
Como contraprestaci贸n por el ejercicio de los warrants existentes, el inversor recibir谩 nuevos warrants no registrados de la Serie A-4 para comprar hasta 6.124.930 acciones ordinarias en una colocaci贸n privada. Los nuevos warrants tendr谩n un precio de ejercicio de 0,67 $ y expirar谩n cinco a帽os despu茅s de la aprobaci贸n de los accionistas. Se espera que la transacci贸n se cierre alrededor del 9 de julio de 2025.
ZyVersa Therapeutics (雮橃姢雼�: ZVSA)電� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 雼澕 旮瓣磤 韴瀽鞛愳檧 鞗岆煱韸� 鞙犽弰 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 鞚� 瓿勳暯鞚� 旮办〈鞚� 鞁滊Μ歃� A-2 氚� A-3 鞗岆煱韸鸽ゼ 0.67雼煬鞚� 頃犾澑霅� 頄夓偓 臧�瓴╈溂搿� 歃夓嫓 頄夓偓頃橃棳 200毵� 雼煬鞚� 齑� 靾橃澋鞚� 彀届稖頃橂姅 雮挫毄鞚� 韽暔頃╇媹雼�.
旮办〈 鞗岆煱韸� 頄夓偓鞐� 雽�頃� 雽�臧�搿� 韴瀽鞛愲姅 牍勲摫搿� 鞁滊Μ歃� A-4 鞁犼窚 鞗岆煱韸鸽ゼ 氚涭晞 斓滊寑 6,124,930欤�鞚� 氤错喌欤茧ゼ 靷 氚╈嫕鞙茧 毵れ瀰頃� 靾� 鞛堨姷雼堧嫟. 鞁犼窚 鞗岆煱韸胳潣 頄夓偓 臧�瓴╈潃 0.67雼煬鞚措┌ 欤检＜ 鞀轨澑 頉� 5雲� 頉� 毵岆霅╇媹雼�. 瓯半灅電� 2025雲� 7鞗� 9鞚�瓴� 鞕勲霅� 鞓堨爼鞛呺媹雼�.
ZyVersa Therapeutics (Nasdaq : ZVSA), une soci茅t茅 biopharmaceutique en phase clinique, a conclu un accord d'incitation aux bons de souscription avec un investisseur institutionnel unique. L'accord pr茅voit l'exercice imm茅diat des bons de souscription existants des s茅ries A-2 et A-3 脿 un prix d'exercice r茅duit de 0,67 $, g茅n茅rant des produits bruts de 2,0 millions de dollars.
En 茅change de l'exercice des bons existants, l'investisseur recevra de nouveaux bons de souscription non enregistr茅s de la s茅rie A-4 lui permettant d'acheter jusqu'脿 6 124 930 actions ordinaires dans le cadre d'un placement priv茅. Les nouveaux bons auront un prix d'exercice de 0,67 $ et expireront cinq ans apr猫s l'approbation des actionnaires. La transaction devrait 锚tre finalis茅e aux alentours du 9 juillet 2025.
ZyVersa Therapeutics (Nasdaq: ZVSA), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat eine Warrant-Induzierungsvereinbarung mit einem einzelnen institutionellen Investor abgeschlossen. Die Vereinbarung umfasst die sofortige Aus眉bung der bestehenden Series A-2 und A-3 Warrants zu einem reduzierten Aus眉bungspreis von 0,67 $, wodurch Bruttoerl枚se in H枚he von 2,0 Millionen Dollar erzielt werden.
Im Gegenzug f眉r die Aus眉bung der bestehenden Warrants erh盲lt der Investor neue nicht registrierte Series A-4 Warrants zum Kauf von bis zu 6.124.930 Aktien des Stammkapitals in einer Privatplatzierung. Die neuen Warrants haben einen Aus眉bungspreis von 0,67 $ und verfallen f眉nf Jahre nach der Zustimmung der Aktion盲re. Der Abschluss der Transaktion wird f眉r etwa 9. Juli 2025 erwartet.
- None.
- Dilutive impact from potential exercise of new warrants for 6,124,930 shares
- Reduced warrant exercise price to $0.67 to incentivize exercise
Insights
ZyVersa secured $2M through warrant transactions, but dilutive structure signals potential capital constraints for this clinical-stage biotech.
This warrant inducement transaction provides ZyVersa with
The mechanics of this transaction are worth noting. The investor is exercising warrants for approximately 3 million shares (957,200 Series A-2 and 2,105,265 Series A-3) but receiving new warrants for over 6 million shares 鈥� more than double the amount exercised. This highly dilutive arrangement indicates ZyVersa likely had few alternatives for raising capital and needed to offer generous terms.
For a clinical-stage biopharmaceutical company developing treatments for renal and inflammatory diseases,
The transaction structure 鈥� with its reduced exercise price and the issuance of additional warrants 鈥� will likely result in significant dilution for existing shareholders if the new warrants are eventually exercised. This dilutive financing approach typically reflects challenging capital-raising conditions for the company.
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; 鈥淶yVersa鈥�), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the 鈥�Series A-2 Warrants鈥�) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the 鈥�Series A-3 Warrants,鈥� and together with the Series A-2 Warrants, the 鈥�Existing Warrants鈥�) at a reduced exercise price of
In consideration for the immediate exercise in full of the Existing Warrants, the investor will receive new Series A-4 unregistered warrants in a private placement to purchase up to 6,124,930 shares of common stock (the 鈥�Series A-4 Warrants鈥� or the 鈥�New Warrants鈥�). The New Warrants will have an exercise price of
A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction.
The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act. The New Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to an accredited institutional investor. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Zyversa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies 鈥� Cholesterol Efflux Mediator鈩� VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit聽.听
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management鈥檚 intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (鈥淶yVersa鈥�) uses words such as 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥減rojects,鈥� 鈥渇uture,鈥� 鈥渋ntends,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥済uidance,鈥� and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa鈥檚 expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa鈥檚 plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa鈥檚 planned preclinical and clinical trials; the timing of the availability of data from ZyVersa鈥檚 preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa鈥檚 plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa鈥檚 product candidates; ZyVersa鈥檚 commercialization, marketing and manufacturing capabilities and strategy; ZyVersa鈥檚 ability to protect its intellectual property position; and ZyVersa鈥檚 estimates regarding future revenue, expenses, capital requirements and need for additional financing.
New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
Corporate, Media, IR Contact
Karen Cashmere
Chief Commercial Officer
[email protected]
786-251-9641
FAQ
What is the purpose of ZVSA's warrant inducement transaction announced on July 8, 2025?
How many new warrants will ZVSA issue in the July 2025 transaction?
What is the exercise price for ZVSA's new Series A-4 warrants?
When will ZVSA's new Series A-4 warrants become exercisable?
Who acted as the financial advisor for ZVSA's warrant inducement transaction?
